Many researchers are exploring the potential of the psychedelic compound psilocybin to treat conditions such as depression and post-traumatic stress disorder.
But psilocybin offers broader therapeutic promise as it appears to spur neuroplasticity, according to Greg McKee, CEO of Tryp Therapeutics (San Diego).
The company is exploring the use of psilocybin-based drugs for treating eating disorders and chronic pain.
“There’s a lot of similarities mechanistically in terms of how psilocybin works to treat depression that we think could apply to treating pain,” McKee said.
Tryp is working with researchers who believe psilocybin can support neuroplasticity in a manner that reduces chronic pain. Tryp’s research partners believe psilocybin can help correct abnormal neural firing in patients with chronic pain and related conditions.
If psilocybin promotes neuroplasticity in huma…